Objective: To explore the association between transfusion of different allogeneic blood components and the risk of venous thromboembolism (VTE) in hospitalized patients, to clarify the differences in thrombotic risk among various blood components, and to develop a targeted VTE risk prediction model. Methods: A retrospective cohort study was conducted, enrolling 5 406 hospitalized patients who received allogeneic blood transfusion in our hospital from November 2024 to October 2025. Using 1∶1 nearest neighbor propensity score matching (PSM), 5 402 non-transfused patients were selected as controls. The matching variables included sex, age, VTE risk score, VTE prophylaxis, comorbid tumor, use of antibiotics, and invasive mechanical ventilation, with a caliper of 0.01 and sampling without replacement. Standardized mean difference (SMD) was used to assess matching quality, with SMD<0.1 indicating balanced baseline characteristics. The transfusion group was stratified by the type of blood component transfused. The chi-square test with Bonferroni correction and multivariate logistic regression (including forced adjustment for the unbalanced variables VTE prophylaxis and antibiotic use) were used to analyze risk factors. A prediction model was constructed and validated using the area under the receiver operating characteristic (ROC) curve and the Hosmer-Lemeshow test. The optimal cut-off value was determined by the maximum Youden index. Results: All variables showed SMD<0.1 after matching, indicating good baseline balance. The incidence of VTE was significantly higher in the transfusion group than in the control group (8.7% vs 4.3%, RR=2.02, 95% CI: 1.74-2.35, P<0.001). Significant differences in VTE incidence were observed among different transfusion subgroups, with a thrombotic risk gradient of combined transfusion > plasma > red blood cells ≈ platelets. The incidence of VTE in the combined transfusion subgroup was 11.7%, which was significantly higher than that in the red blood cell subgroup (RR=3.20, 95% CI: 2.41-4.24, P<0.001), plasma subgroup (RR=1.71, 95% CI: 1.24-2.35, P<0.001), and platelet subgroup (RR=6.81, 95% CI: 2.56-18.06, P<0.001). The prediction model showed good discrimination and calibration, with an area under the ROC curve of 0.800. The optimal cut-off value determined by the Youden index was 0.12, corresponding to a sensitivity of 62.3% and a negative predictive value of 91.4%. Conclusion: Allogeneic blood transfusion was an independent risk factor for VTE in hospitalized patients, with significant differences in thrombotic risk among different blood components. The prediction model developed in this study can achieve VTE risk stratification in transfused patients, providing evidence for precise transfusion therapy and patient blood management.

Eight compounds were isolated and purified from the ethyl acetate part of 70% acetone extract of Rehmannia glutinosa by various chromatographic techniques such as silica gel, MCI gel CHP-20, ODS, Toyopearl HW-40C, combined with TLC and semi-preparative HPLC. Their structures were elucidated by modern spectroscopy techniques (NMR, MS, UV, IR), and identified as neomartynoside A (1), osmanthuside B₆ (2), martynoside (3), isomartynoside (4), (E)-p-hydroxycinnamic acid (5), caffeic acid (6), ferulic acid (7), and methyl caffeate (8). Compound 1 is a new phenylethanol glycoside, which was identified as neomartynoside A. Compound 2 was isolated from Rehmannia glutinosa for the first time. In addition, compounds 2, 6 and 7 significantly increased relative glucose consumption, showing potential hypoglycemic activity.

OBJECTIVE: To explore the therapeutic effects and underlying mechanisms of Dendrobium officinale (Tiepi Shihu) extract (DOE) on insomnia. METHODS: Forty-two male Sprague-Dawley rats were randomly divided into 6 groups (n=7 per group): normal control, model control, melatonin (MT, 40 mg/kg), and 3-dose DOE (0.25, 0.50, and 1.00 g/kg) groups. Rats were raised in a strong-light (10,000 LUX) and -noise (>80 db) environment (12 h/d) for 16 weeks to induce insomnia, and from week 10 to week 16, MT and DOE were correspondingly administered to rats. The behavior tests including sodium pentobarbital-induced sleep experiment, sucrose preference test, and autonomous activity test were used to evaluate changes in sleep and emotions of rats. The metabolic-related indicators such as blood pressure, blood viscosity, blood glucose, and uric acid in rats were measured. The pathological changes in the cornu ammonis 1 (CA1) region of rat brain were evaluated using hematoxylin and eosin staining and Nissl staining. Additionally, the sleep-related factors gamma-aminobutyric acid (GABA), glutamate (GA), 5-hydroxytryptamine (5-HT), and interleukin-6 (IL-6) were measured using enzyme linked immunosorbent assay. Finally, we screened potential sleep-improving receptors of DOE using polymerase chain reaction (PCR) array and validated the results with quantitative PCR and immunohistochemistry. RESULTS: DOE significantly improved rats' sleep and mood, increased the sodium pentobarbital-induced sleep time and sucrose preference index, and reduced autonomic activity times (P<0.05 or P<0.01). DOE also had a good effect on metabolic abnormalities, significantly reducing triglyceride, blood glucose, blood pressure, and blood viscosity indicators (P<0.05 or P<0.01). DOE significantly increased the GABA content in hippocampus and reduced the GA/GABA ratio and IL-6 level (P<0.05 or P<0.01). In addition, DOE improved the pathological changes such as the disorder of cell arrangement in the hippocampus and the decrease of Nissel bodies. Seven differential genes were screened by PCR array, and the GABA_A receptors (Gabra5, Gabra6, Gabrq) were selected for verification. The results showed that DOE could up-regulate their expressions (P<0.05 or P<0.01). CONCLUSION DOE demonstrated remarkable potential for improving insomnia, which may be through regulating GABA_A receptors expressions and GA/GABA ratio.
Animals ; Dendrobium/chemistry* ; Rats, Sprague-Dawley ; Male ; Sleep Initiation and Maintenance Disorders/blood* ; Plant Extracts/therapeutic use* ; Receptors, GABA-A/metabolism* ; Noise/adverse effects* ; Light/adverse effects* ; gamma-Aminobutyric Acid/metabolism* ; Sleep/drug effects* ; Rats ; Receptors, GABA/metabolism*

Objective To investigate the related risk factors for calf muscular venous thrombosis(CMVT)complicated with pulmonary embolism(PE),and to provide new theoretical basis for clinical diagnosis and treatment of CMVT patients.Methods A total of 200 CMVT patients were selected.CMVT patients with PE during hospitalization and within six months after discharge were selected as the PE group,and CMVT patients without PE were selected as the non-PE group.The differences in clinical data between the two groups were compared.Logistic regression analysis was performed to identify the independent factors of CMVT complicated with PE and to establish the clinical prediction model of CMVT complicated with PE.Results Among the 200 patients,36 cases were classified in the PE group,and 164 cases were classified in the non-PE group,resulting in an incidence rate of 18％.Logistic regression analysis indicated that"surgery","fracture",and"tumor"were identified as independent risk factors for developing PE in CMVT patients.Conversely,"anticoagulation"was a protective factor against PE in CMVT patients.Based on this,a regression equation model was established,with the predicted overall accuracy of 89.5％.The prediction model was analyzed using the Bootstrap resampling method,yielding an area under the curve(AUC)of 0.909 and a C-index of 0.908 7[95％confidence interval(CI)0.856 2-0.961 2].These results indicated that the prediction model exhibited superior discriminatory ability in distinguishing between patients with PE and those without.Conclusion Surgery,fracture,and tumor are independent risk factors for PE in patients with CMVT.Anticoagulant therapy is recommended for preventing complications such as PE in cases of CMVT.The constructed clinical prediction model of CMVT complicated with PE can provide reference for the treatment and prognosis of CMVT patients.

Objective:To investigate the impact of plasmapheresis therapy on the clinical efficacy in predicted severe hypertriglyceridemia-associated acute pancreatitis (HTG-AP) patients.Methods:The clinical data of 500 HTG-AP patients admitted to 36 medical centers across China in the Chinese Acute Pancreatitis Clinical Trials Group-PERFORM database from November 2020 to June 2023 were retrospectively analyzed. Besides the inclusion and exclusion criteria from PERFORM study, patients who had acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score ≥8 or CRP>150 mg/L on admission were included in the final analyses ( n=189). Patients were categorized into the plasmapheresis group ( n=51) and the routine treatment group ( n=138) according to the triglyceride-lowering therapies they received. General data, laboratory findings, AP severity, and clinical outcomes were recorded. Results:Patients undergoing plasmapheresis had higher initial triglyceride levels, APACHEⅡ score, SOFA score, and more organ failure than those receiving routine medical treatment. Results of multivariable logistic regression models showed that the plasmapheresis group, as compared to the routine treatment group, was neither associated with decreased risk of persistent organ failure within 14 days [54.9% (28/51) vs 37.7% (52/138), OR=0.89, 95% CI 0.36-2.21, P=0.810], nor with reduced incidence of organ failure on day 7 [17.7% (9/51) vs 15.9% (22/138), OR=0.60, 95% CI 0.19-1.88, P=0.378]. There was no significant difference on the dynamic changes of serum triglyceride within the first three days of admission ( P=0.108). Conclusions:Early plasmapheresis is not associated with reduced incidence of persistent organ failure in predicted severe HTG-AP patients.

Objective:To investigate the impact of plasmapheresis therapy on the clinical efficacy in predicted severe hypertriglyceridemia-associated acute pancreatitis (HTG-AP) patients.Methods:The clinical data of 500 HTG-AP patients admitted to 36 medical centers across China in the Chinese Acute Pancreatitis Clinical Trials Group-PERFORM database from November 2020 to June 2023 were retrospectively analyzed. Besides the inclusion and exclusion criteria from PERFORM study, patients who had acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score ≥8 or CRP>150 mg/L on admission were included in the final analyses ( n=189). Patients were categorized into the plasmapheresis group ( n=51) and the routine treatment group ( n=138) according to the triglyceride-lowering therapies they received. General data, laboratory findings, AP severity, and clinical outcomes were recorded. Results:Patients undergoing plasmapheresis had higher initial triglyceride levels, APACHEⅡ score, SOFA score, and more organ failure than those receiving routine medical treatment. Results of multivariable logistic regression models showed that the plasmapheresis group, as compared to the routine treatment group, was neither associated with decreased risk of persistent organ failure within 14 days [54.9% (28/51) vs 37.7% (52/138), OR=0.89, 95% CI 0.36-2.21, P=0.810], nor with reduced incidence of organ failure on day 7 [17.7% (9/51) vs 15.9% (22/138), OR=0.60, 95% CI 0.19-1.88, P=0.378]. There was no significant difference on the dynamic changes of serum triglyceride within the first three days of admission ( P=0.108). Conclusions:Early plasmapheresis is not associated with reduced incidence of persistent organ failure in predicted severe HTG-AP patients.

Objective To investigate the related risk factors for calf muscular venous thrombosis(CMVT)complicated with pulmonary embolism(PE),and to provide new theoretical basis for clinical diagnosis and treatment of CMVT patients.Methods A total of 200 CMVT patients were selected.CMVT patients with PE during hospitalization and within six months after discharge were selected as the PE group,and CMVT patients without PE were selected as the non-PE group.The differences in clinical data between the two groups were compared.Logistic regression analysis was performed to identify the independent factors of CMVT complicated with PE and to establish the clinical prediction model of CMVT complicated with PE.Results Among the 200 patients,36 cases were classified in the PE group,and 164 cases were classified in the non-PE group,resulting in an incidence rate of 18％.Logistic regression analysis indicated that"surgery","fracture",and"tumor"were identified as independent risk factors for developing PE in CMVT patients.Conversely,"anticoagulation"was a protective factor against PE in CMVT patients.Based on this,a regression equation model was established,with the predicted overall accuracy of 89.5％.The prediction model was analyzed using the Bootstrap resampling method,yielding an area under the curve(AUC)of 0.909 and a C-index of 0.908 7[95％confidence interval(CI)0.856 2-0.961 2].These results indicated that the prediction model exhibited superior discriminatory ability in distinguishing between patients with PE and those without.Conclusion Surgery,fracture,and tumor are independent risk factors for PE in patients with CMVT.Anticoagulant therapy is recommended for preventing complications such as PE in cases of CMVT.The constructed clinical prediction model of CMVT complicated with PE can provide reference for the treatment and prognosis of CMVT patients.

The 95% ethanol extract of Poria cocos was separated and purified by ODS, MCI gel CHP20 and silica gel column chromatography combined with the semi-preparative HPLC. The chemical structures of the isolated compounds were identified by NMR, MS, IR, and calculated NMR methods. Seven compounds were isolated from Poria cocos and identified as 20S-2β,3α,15α,19,20-hydroxy-pregnane-7-ene (1), dehydroeburicoic acid monoacetate (2), eburicoic acid acetate (3), dehydroeburicoic acid (4), eburicoic acid (5), dehydropachymic acid (6), pachymic acid (7). Compound 1 is a new pregnane steroid.

Background::Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography (ERCP), the benefits and safety of high-carbohydrate fluid diet (CFD) intake 2 h before ERCP remain unclear. This study aimed to analyze whether high-CFD intake 2 h before ERCP can be safe and accelerate patients’ recovery.Methods::This prospective, multicenter, randomized controlled trial involved 15 tertiary ERCP centers. A total of 1330 patients were randomized into CFD group ( n = 665) and fasting group ( n = 665). The CFD group received 400 mL of maltodextrin orally 2 h before ERCP, while the control group abstained from food/water overnight (>6 h) before ERCP. All ERCP procedures were performed using deep sedation with intravenous propofol. The investigators were blinded but not the patients. The primary outcomes included postoperative fatigue and abdominal pain score, and the secondary outcomes included complications and changes in metabolic indicators. The outcomes were analyzed according to a modified intention-to-treat principle. Results::The post-ERCP fatigue scores were significantly lower at 4 h (4.1 ± 2.6 vs. 4.8 ± 2.8, t = 4.23, P <0.001) and 20 h (2.4 ± 2.1 vs. 3.4 ± 2.4, t= 7.94, P <0.001) in the CFD group, with least-squares mean differences of 0.48 (95% confidence interval [CI]: 0.26–0.71, P <0.001) and 0.76 (95% CI: 0.57–0.95, P <0.001), respectively. The 4-h pain scores (2.1 ± 1.7 vs. 2.2 ± 1.7, t = 2.60, P = 0.009, with a least-squares mean difference of 0.21 [95% CI: 0.05–0.37]) and positive urine ketone levels (7.7% [39/509] vs. 15.4% [82/533], χ2 = 15.13, P <0.001) were lower in the CFD group. The CFD group had significantly less cholangitis (2.1% [13/634] vs. 4.0% [26/658], χ2 = 3.99, P = 0.046) but not pancreatitis (5.5% [35/634] vs. 6.5% [43/658], χ2 = 0.59, P = 0.444). Subgroup analysis revealed that CFD reduced the incidence of complications in patients with native papilla (odds ratio [OR]: 0.61, 95% CI: 0.39–0.95, P = 0.028) in the multivariable models. Conclusion::Ingesting 400 mL of CFD 2 h before ERCP is safe, with a reduction in post-ERCP fatigue, abdominal pain, and cholangitis during recovery.Trail Registration::ClinicalTrials.gov, No. NCT03075280.

The current situation of medical simulation technology was introduced when applied in medical service of foreign armies.The current situation and problems of medical simulation technology in mobile medical service detachment training of the PLA were described.Some suggestions were put forward including completing medical simulation management system,optimizing personnel managment and training mode and promoting standardization and modular construction of medical simulation system.References were provided for enhancing combat-oriented training and medical service support capability of levels of medical service institutions and mobile medical service detachment of the PLA.[Chinese Medical Equipment Journal,2024,45(10):88-92]